FKBP8 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL8288590	0.76	1/20
SCHEMBL7003055	0.74	1/20
SCHEMBL7002920	0.70	1/20
SCHEMBL11324603	0.66	1/20
SCHEMBL26293177	0.64	1/20
SCHEMBL26294993	0.63	1/20
SCHEMBL7003174	0.62	1/20
SCHEMBL8277600	0.62	1/20
SCHEMBL13856578	0.62	1/20
SCHEMBL18180597	0.62	1/20
SCHEMBL13856429	0.61	1/20
SCHEMBL11332843	0.60	1/20
SCHEMBL17817446	0.60	1/20
SCHEMBL1895132	0.60	1/20
SCHEMBL13856422	0.60	1/20
SCHEMBL26293182	0.59	1/20
SCHEMBL26293211	0.58	1/20
SCHEMBL4091316	0.57	1/20
SCHEMBL20831148	0.57	1/20
SCHEMBL26293025	0.57	1/20

Clinical trials — most relevant to FKBP8 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Topical Metformin Emulgel VS Salicylic Acid Peeling in Treatment of Acne Vulgaris	PHASE4	UNKNOWN
Utilising Genotype Informed Bayesian Dosing of Tacrolimus in Children Post Solid Organ Transplantation.	PHASE4	RECRUITING
Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032)	PHASE4	COMPLETED
Study to Evaluate the Safety and Efficacy of Switching Calcineurin Inhibitor to Everolimus After Kidney Transplantation in Adults	PHASE4	UNKNOWN
Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL)	PHASE2	COMPLETED
FK506 (Tacrolimus) in Pulmonary Arterial Hypertension	PHASE2	COMPLETED
Cyclosporine For The Treatment Of COVID-19(+)	PHASE2	COMPLETED
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer	PHASE2	COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension	PHASE1/PHASE2	RECRUITING
Early Conversion From CNI to Belatacept in Renal Transplant Recipients With Delayed and Slow Graft Function	PHASE2	UNKNOWN
Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study	PHASE2	COMPLETED
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors	PHASE1	WITHDRAWN
Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma	PHASE1	COMPLETED
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors	PHASE1	COMPLETED
FKBP5 Methylation and Childhood Emotional Abuse in Complex Posttraumatic Stress Disorder: Investigating the Relationship and Its Predictive Role in Therapy Outcome	nan	COMPLETED
Research and Application for New Clinical Diagnosis and Treatment System for HBV Related HCC Liver Transplantation	nan	COMPLETED
Clinical Implications of FKBP5 in Stroke	nan	UNKNOWN
Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer	nan	WITHDRAWN
Genetic Predictors of Lithium Response in Bipolar Disorder	nan	COMPLETED
Quantification of GADD34 Expression in RA	nan	COMPLETED
Gene Polymorphisms in Tacrolimus Drug Interactions	nan	COMPLETED
Cortisol, Hippocampus, and Insula in Anorexia Nervosa.	nan	RECRUITING
Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia	nan	COMPLETED
Multi-level Molecular Profiling of High Acute Stress: a Clinical Study	nan	UNKNOWN
Alopecia Areata Registry	nan	ACTIVE_NOT_RECRUITING
Genetic Variants Associated With Adolescent Suicide Attempts	nan	COMPLETED
Evaluation of Interaction Between Immunosuppressive Drugs and Protein-bound Uremic Toxins in Renal Transplant Patients	nan	WITHDRAWN
Pharmacogenetic and Neurofunctional Brain Areas Study in Obese Patients With Binge Eating Disorder	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a FKBP8 binder may also engage these)

Protein	Name	Similarity
O35465	—	1.000	O35465 →
Q3B7U9	—	0.997	Q3B7U9 →
Q496Y0	—	0.978	Q496Y0 →
A1A4I4	—	0.971	A1A4I4 →
PKN1	Serine/threonine-protein kinase N1	0.970	landscape →
Q8BNV1	—	0.969	Q8BNV1 →
Q8HXH0	—	0.969	Q8HXH0 →
TERF2IP	Telomeric repeat-binding factor 2-interacting protein 1	0.968	landscape →
Q9D4H7	—	0.968	Q9D4H7 →
Q9Y2B5	—	0.967	Q9Y2B5 →
Q6IMX7	—	0.967	Q6IMX7 →
P70268	—	0.967	P70268 →
Q63433	—	0.966	Q63433 →
Q920N2	—	0.965	Q920N2 →
HSPBP1	Hsp70-binding protein 1	0.965	landscape →
P41214	—	0.965	P41214 →
Q8R1T1	—	0.964	Q8R1T1 →
Q9BUR4	—	0.964	Q9BUR4 →
Q8IYL2	—	0.964	Q8IYL2 →
Q4R4I0	—	0.964	Q4R4I0 →
Q8C190	—	0.963	Q8C190 →
Q99P31	—	0.963	Q99P31 →
Q9D2Q2	—	0.963	Q9D2Q2 →
Q58CR3	—	0.963	Q58CR3 →
Q6IR34	—	0.963	Q6IR34 →
MAP4K2	Mitogen-activated protein kinase kinase kinase kinase 2	0.962	landscape →
Q5TM59	—	0.962	Q5TM59 →
Q6ZT62	—	0.961	Q6ZT62 →
Q8BY35	—	0.961	Q8BY35 →
Q9BZE9	—	0.961	Q9BZE9 →